ImmuPharma (LON:IMM) Trading Up 22.1% - Here's What Happened

Key Points

• ImmuPharma plc's stock rose by 22.1% during mid-day trading, reaching a high of GBX 15.15 ($0.20), compared to a previous close of GBX 11.13 ($0.15).
• The company reported quarterly earnings with earnings per share (EPS) at GBX (0.38) and analysts project a current year EPS of -339.0000022.
• ImmuPharma specializes in peptide-based therapeutics, with its lead program, Lupuzor™, aimed at treating Lupus and potentially other autoimmune diseases.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 22.1% on Wednesday . The company traded as high as GBX 15.15 ($0.21) and last traded at GBX 13.59 ($0.18). 32,838,160 shares were traded during trading, an increase of 327% from the average session volume of 7,683,062 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Price Performance

The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The business's 50-day simple moving average is GBX 3.12 and its two-hundred day simple moving average is GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, sell-side analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.